Streamex Corp. reports a wider-than-expected Q1 GAAP loss, missing analyst estimates by $0.24 per share. Streamex Corp. reported a Q1 GAAP loss of $0.27 per share, missing estimates by $0.24. The company cited ongoing operational challenges as a key factor in the underperf
The closed-end fund reported $6.1 million net investment income and a slight NAV increase to $16.71 per share. Barings Corporate Investors reported first-quarter GAAP net investment income of $0.30 per share, aligning with its financial performance. The Board declared a $0
Investors trim exposure in Asia as US-China trade talks resume, with South Korea’s benchmark index falling sharply from record levels. Asian stocks declined Friday, reversing Wall Street’s overnight gains as investors awaited high-stakes talks between US President Donald T
Intrusion Inc. announces a $4M annual contract and targets cash flow positivity by year-end 2026 despite Q1 setbacks. Intrusion Inc. (INTZ) has signed a $4M annual contract with a Texas-based entity, aiming to achieve cash flow positivity by the end of 2026. The company ci
NNE outlines plans to begin microreactor construction at University of Illinois in mid- to late 2027 pending NRC approval. Nano Nuclear Energy Inc. (NNE) expects to start construction of its first microreactor at the University of Illinois in mid- to late 2027. The timelin
Xos reaffirms its 2026 revenue guidance while pivoting its business mix toward higher-margin hubs and powertrain segments. Xos Inc. (XOS) confirmed its 2026 revenue projection of $40M to $50M during its Q1 2026 earnings call, citing a strong start to the year. The company
CVD Equipment outlines $1.8m cost reduction plan CVD Equipment Corporation has announced a $1.8m cost reduction plan for Q1 2026. The plan is part of the company's efforts to improve its financial performance. The company also received $14.8m in net proceed
The company cites stronger trucking sector orders as it projects second-quarter net sales of approximately $13.2 million. Dragonfly Energy Holdings Corp. (DFLI) expects Q2 net sales to reach about $13.2 million, driven by rising demand in the trucking sector. The outlook f
The biotech firm targets Q1 2026 for a pivotal trial of its non-hormonal contraceptive while anticipating Flora Sync LF5 revenue in June. Daré Bioscience outlined plans to advance its Ovaprene contraceptive into a Phase III trial in 2026, targeting 2,500 exposure cycles. T
Earnings Call Insights: Virgin Galactic (SPCE) Q1 2026 Management View Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inheren
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.